Key Insights

Highlights

Treatment Research

2 treatments under study, led by Lumigan 01 Mgml Eye Drops Solution

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
SYF7f0bb36dc72742e59a1e09009bca22fePhase 3Unknown

RANDOMIZED, OPEN LABEL, PARALLEL-GROUP, TWO-ARM, MULTICENTER STUDY WITH CLINICAL ENDPOINT COMPARING PRESERVATIVE FREE BIMATOPROST OPHTHALMIC SOLUTION 0.1 MG/ML AND LUMIGAN® (BIMATOPROST OPHTHALMIC SOLUTION) 0.1 MG/ML IN PATIENTS WITH CHRONIC OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN ONE OR BOTH EYES.

Showing all 1 trials

Research Network

Common Treatments

  • Lumigan 01 Mgml Eye Drops Solution1
  • Bimatoprost 01 Mgml1

Active Sponsors

  • Genetic s.p.a.1

Related Conditions

  • Ocular Hypertension1

Activity Timeline